A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC).
The following drug will be involved in this study :
A Phase II study of Lorlatinib (PF-06463922) in advanced ALK and ROS1 rearranged NSCLC with CNS metastasis in the absence of measurable extracranial lesions
- ClinicalTrials.gov Identifier: NCT02927340
- Protocol Number: 16-248
- Principal Investigator: Daniel Costa
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required